Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL2217317 | 0.94 | IDO1 (0.50) | IDO1LOXL2TAAR1MAOBAGXT | |
| Hydrochloric Acid SCHEMBL582206 | 0.94 | IDO1 (0.50) | IDO1LOXL2TAAR1MAOBAGXT | |
| Bromide SCHEMBL3297378 | 0.78 | TAAR1 (0.54) | IDO1LOXL2TAAR1MAOBAGXT | |
| SCHEMBL1500706 | 0.73 | — | — | |
| Iodide SCHEMBL7545274 | 0.72 | TAAR1 (0.54) | IDO1LOXL2TAAR1MAOBAGXT | |
| SCHEMBL16561361 | 0.71 | IDO1 (0.58) | IDO1LOXL2TAAR1MAOBAGXT | |
| SCHEMBL7437052 | 0.71 | TAAR1 (0.68) | IDO1LOXL2TAAR1MAOBAGXT | |
| SCHEMBL1468357 | 0.71 | IDO1 (0.58) | IDO1LOXL2TAAR1MAOBAGXT | |
| Bromide SCHEMBL1980350 | 0.71 | CYP2A6 (0.47) | IDO1TAAR1 | |
| Bromide SCHEMBL2206420 | 0.71 | IDO1 (0.50) | IDO1TAAR1AGXTLMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIV SCI & TECH NTNU (NO) | 2025-11-20 | — | — | US | disclosed |
| EP-4578856-A1 | HETEROCYCLIC COMPOUND | Ubience Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| WO-2024079342-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2024-04-18 | — | — | WO | disclosed |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-2024071371-A1 | HETEROCYCLIC COMPOUND | ユビエンス株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | ASTRAZENECA UK LIMITED | 2002-05-02 | — | — | US | disclosed |
| US-6342765-B1 | COMPOUNDS THAT INHIBIT FARNESYLATION OF MUTANT RAS GENE PRODUCTS; TREATING DISEASES, ESPECIALLY CANCER, WHICH ARE MEDIATED THROUGH FARNESYLATION OF RAS | ASTRAZENECA UK LIMITED (GB) | 2002-01-29 | — | — | US | disclosed |
| EP-1025088-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-05 | — | — | EP | disclosed |
| EP-1025088-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | AstraZeneca UK Limited (GB) | 2000-08-09 | — | — | EP | disclosed |
| EP-1025089-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020611-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020612-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| US-5580989-A | Process for the preparation of N-4-[(substituted phenyl)alkylheterocyclic]-N | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0726897-A1 | PROCESS FOR THE PREPARATION OF N-4- (SUBSTITUTED PHENYL)ALKYLTHIENYL]-, AND N-4- (SUBSTITUTED PHENYL)ALKYLFURYL]BUT-3-YN-2-YL]-N-HYDROXYUREA COMPOUNDS | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012589-A1 | PROCESS FOR THE PREPARATION OF N-4-[(SUBSTITUTED PHENYL)ALKYLTHIENYL]-, AND N-4-[(SUBSTITUTED PHENYL)ALKYLFURYL]BUT-3-YN-2-YL]-N-HYDROXYUREA COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | CHRM2 1942/4885IDO1 2317/4885LOXL2 3096/4885 |
| US-11608339-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, TPH2 | CHRM2 74/4885IDO1 275/4885LOXL2 477/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | CHRM2 512/4885IDO1 752/4885LOXL2 1191/4885 |
| US-20020052376-A1 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors | FNTA, FNTB, RABGGTA | CHRM2 3190/4885IDO1 2367/4885LOXL2 4271/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | CHRM2 2701/4885IDO1 4235/4885LOXL2 2410/4885 |
| US-20250353856-A1 | COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) | CSF1R, CSF3R, IL1RN | CHRM2 2629/4885IDO1 1572/4885LOXL2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.